Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors is a study aimed at adults with tough-to-treat cancers. In this study, doctors use a special type of treatment called 'CAR-T cell therapy' which involves using a person's own immune cells, modified to target their cancer more effectively. They choose the best match from a library of dual-target pairs based on several criteria, like how the targets are expressed in the tumor compared to normal tissues.

• The study lasts for up to 15 years with participants followed closely for the first 24 months.
• Participants receive a treatment called lymphodepletion before getting the CAR-T therapy.
• This study is mostly for adults (18-75 years) whose cancers can't be cured with standard treatments.

Participants must meet certain health criteria to join, like having a specific type of tumor and being able to undergo treatment. The study aims to see if this new approach can better control tumors while being safe for patients.